Search hospitals > Texas > Austin
Central Texas Clinical Research
Claim this profileAustin, Texas 78705
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in HIV
Conducts research for Healthy Subjects
Conducts research for HIV/AIDS
Conducts research for Type 2 Diabetes
119 reported clinical trials
2 medical researchers
Summary
Central Texas Clinical Research is a medical facility located in Austin, Texas. This center is recognized for care of Human Immunodeficiency Virus Infection, HIV, Healthy Subjects, HIV/AIDS, Type 2 Diabetes and other specialties. Central Texas Clinical Research is involved with conducting 119 clinical trials across 83 conditions. There are 2 research doctors associated with this hospital, such as Cynthia C Brinson and Brinson.Area of expertise
1Human Immunodeficiency Virus Infection
Global LeaderD67N positive
M41L positive
L210W positive
2HIV
Global LeaderTop PIs
Cynthia C BrinsonCentral Texas Clinical Research, LLC1 year of reported clinical research
Studies Coronavirus
Studies Human Immunodeficiency Virus Infection
3 reported clinical trials
6 drugs studied
BrinsonCentral Texas Clinical Research2 years of reported clinical research
Studies Cardiovascular Disease
Studies Atherosclerosis
1 reported clinical trial
2 drugs studied
Clinical Trials running at Central Texas Clinical Research
HIV
Ulcerative Colitis
Coronavirus
Inflammatory Bowel Disease
Ulcer
Type 2 Diabetes
Schizophrenia
Dermatomyositis
Crohn's Disease
Human Immunodeficiency Virus Infection
Bictegravir + Lenacapavir
for HIV
This trial is testing two HIV medications, bictegravir and lenacapavir, either separately or combined into one pill. It aims to see if these new treatments work better than current therapies for people living with HIV. These drugs help control HIV by stopping the virus from making more copies of itself. Bictegravir is a newly approved medication combined with other drugs, while lenacapavir is a long-acting medication recently approved in the EU.
Recruiting1 award Phase 2 & 36 criteria
Bictegravir + Lenacapavir
for HIV
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH). The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH.
Recruiting1 award Phase 3
DOR/ISL
for HIV
This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL \[MK-8591A\]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.
Recruiting1 award Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Central Texas Clinical Research?
Central Texas Clinical Research is a medical facility located in Austin, Texas. This center is recognized for care of Human Immunodeficiency Virus Infection, HIV, Healthy Subjects, HIV/AIDS, Type 2 Diabetes and other specialties. Central Texas Clinical Research is involved with conducting 119 clinical trials across 83 conditions. There are 2 research doctors associated with this hospital, such as Cynthia C Brinson and Brinson.